News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
All Stories
Press Release
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
May 16, 2023
Read Now
Press Release
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
May 16, 2023
Read Now
News
Biotech Scribe strikes gene editing deal with Lilly subsidiary
May 16, 2023
Biopharma Dive
Read Now
Press Release
Biotech Scribe strikes gene editing deal with Lilly subsidiary
May 16, 2023
Biopharma Dive
Read Now
News
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
May 16, 2023
Genetic Engineering & Biotechnology News
Read Now
Press Release
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
May 16, 2023
Genetic Engineering & Biotechnology News
Read Now
News
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
Press Release
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now